$7.27
+0.09(1.25%)
Mkt Cap $12M
$3.09
$15.72
52-Week Range
At a Glance
AI-generated6-K
Kazia Therapeutics released its March 2026 corporate overview and fact sheet, highlighting paxalisib clinical progress in TNBC and GBM, NDL2 development toward IND in 2026, and US$46 million cash runway into 2029.$12M
Market Cap
$14.7K
Revenue
-$17M
Net Income
Employees9
Fundamentals
How The Business Makes Money
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Industry Biotechnology
Activity
Company Profile
CIK0001075880
ISINUS48669G3039
CUSIP48669G303
Phone1300 787 272
AddressThree International Towers, Sydney, NSW, 2000, AU
SEC EDGAR